本文選題：骨外傷病人 + 耐甲氧西林金黃色葡萄球菌��； 參考：《中國(guó)病原生物學(xué)雜志》2016年11期

【摘要】：目的研究骨外傷病人耐甲氧西林金黃色葡萄球菌(MRSA)的耐藥性變遷及相關(guān)感染因素,為控制病原菌感染及耐藥性發(fā)展提供指導(dǎo)。方法收集本院2012-2015年骨外傷病人傷口分泌物等標(biāo)本分離病原菌,鑒定MRSA菌株并進(jìn)行藥敏試驗(yàn),對(duì)耐藥性及影響因素進(jìn)行分析。結(jié)果 1 874例骨外傷患者中共分離MRSA179株,其中分離自傷口分泌物、膿液分泌物、中心靜脈血、痰咽拭子以及鼻拭子標(biāo)本中的MRSA菌株數(shù)分別為72、46、33、19和9株。2012-2015年各年度分離菌株數(shù)分別為27、33、55和64株。2012年MRSA臨床分離株對(duì)頭孢唑啉、頭孢噻肟、慶大霉素、環(huán)丙沙星、四環(huán)素、左氧氟沙星、克林霉素、萬(wàn)古霉素的耐藥率分別為51.85%、33.33%、29.63%、22.22%、85.19%、37.04%、59.26%、0.00%;2013年MRSA耐藥率分別為57.58%、33.33%、42.42%、33.33%、75.76%、51.52%、51.52%、0.00%;2014年MRSA耐藥率分別為67.27%、38.18%、45.45%、36.36%、81.82%、49.09%、60.00%、0.00%;2015年MRSA耐藥率分別為68.75%、42.19%、46.88%、39.06%、82.81%、60.94%、71.88%、0.00%。2012-2015年MRSA對(duì)萬(wàn)古霉素敏感,對(duì)其他各檢測(cè)抗菌藥物的耐藥率呈逐年升高趨勢(shì)�；颊叩哪挲g和治療中聯(lián)合用藥種類(lèi)與其感染MRSA的發(fā)生無(wú)關(guān)(P0.05),而骨外傷患者感染MRSA的發(fā)生與患者性別、住院時(shí)間長(zhǎng)短、是否接受手術(shù)治療以及自身是否患有糖尿病有關(guān)(P0.01)。結(jié)論骨外傷病人感染MRSA以傷口分泌物樣本居多,菌株對(duì)各種抗菌藥物的耐藥程度呈整體增高趨勢(shì),但對(duì)萬(wàn)古霉素敏感。骨外傷病人MRSA感染治療時(shí)時(shí)應(yīng)考慮住院時(shí)間、是否接受手術(shù)治療以及是否患有糖尿病等因素。
[Abstract]:Objective to study the changes of drug resistance of methicillin-resistant Staphylococcus aureus (MRSA) and the related infection factors in bone trauma patients, and to provide guidance for the control of pathogenic bacteria infection and the development of drug resistance. Methods pathogenic bacteria were isolated from wound secretion of bone trauma patients in our hospital from 2012 to 2015. MRSA strains were identified and drug sensitivity test was carried out. Drug resistance and influencing factors were analyzed. Results the MRSA 179 strains were isolated from 1 874 patients with bone trauma, including wound secretions, pus secretions and central venous blood. The number of MRSA strains in sputum swabs and nasal swabs were 722, 46, 3319 and 9 strains, respectively. In 2012-2015, the number of MRSA isolates in each year were 270.35 and 64, respectively. The clinical isolates of MRSA in 2012 were cefazolin, cefotaxime, gentamicin, ciprofloxacin, tetracycline, cefazolin, cefotaxime, gentamycin, ciprofloxacin and tetracycline, respectively. 宸︽哀姘熸矙鏄，

本文編號(hào)：2105415